The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty‐eight–day, multicenter, phase II, randomized, double‐blind, placebo‐controlled, dose‐response clinical trial examining safety and efficacy in patients with gout
Abstract
Objective: Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in establishing normal serum urate (sUA) concentrations in gout patients with hyperuricemia (≥8.0 mg/dl). Methods: We conducted a phase II, randomized, double‐blind, placebo‐controlled trial in 153 patients (ages 23–80 years). Subjects received febuxostat (40 mg, 80 mg, 120 mg) or placebo once daily for 28 days and colchicine prophylaxis for 14 days prior to and 14 days after randomization. The primary end point was the proportion of subjects with sUA levels <6.0 mg/dl on day 28. Results: Greater proportions of febuxostat‐treated patients than placebo‐treated patients achieved an sUA level <6.0 mg/dl at each visit (P < 0.001 for each comparison). The targeted sUA level was attained on day 28 in 0% of those taking placebo and in 56% of those taking 40 mg, 76% taking 80 mg, and 94% taking 120 mg of febuxostat. The mean sUA reduction from baseline to day 28 was 2% in the placebo group and 37% in the 40‐mg, 44% in the 80‐mg, and 59% in the 120‐mg febuxostat groups. Gout flares occurred with similar frequency in the placebo (37%) and 40‐mg febuxostat (35%) groups and with increased frequency in the higher dosage febuxostat groups (43% taking 80 mg; 55% taking 120 mg). During colchicine prophylaxis, gout flares occurred less frequently (8–13%). Incidences of treatment‐related adverse events were similar in the febuxostat and placebo groups. Conclusion: Treatment with febuxostat resulted in a significant reduction of sUA levels at all dosages. Febuxostat therapy was safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Harrison's Principles of Internal Medicine.
(1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-1-167_1 · Cited by 1,523
Preliminary criteria for the classification of the acute arthritis of primary gout
Wallace, S. L., Robinson, H., Masi, A. T., Decker, J. L., Mccarty, D. J., & Yü, T. (1977) · Arthritis & Rheumatism · doi:10.1002/art.1780200320 · Cited by 1,432
Asymptomatic hyperuricemia. Risks and consequences in the normative aging study
Campion, E. W., Glynn, R. J., & Delabry, L. O. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90441-4 · Cited by 851
Hande, K. R., Noone, R. M., & Stone, W. J. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90743-5 · Cited by 680
Emmerson, B. T. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602153340707 · Cited by 516
Epidemiology of gout and hyperuricemia
Hall, A. P., Barry, P. E., Dawber, T. R., & McNamara, P. M. (1967) · The American Journal of Medicine · doi:10.1016/0002-9343(67)90004-6 · Cited by 482
Terkeltaub, R. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp030733 · Cited by 456
Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic gout
Perez‐Ruiz, F., Calabozo, M., Pijoan, J. I., Herrero‐Beites, A. M., & Ruibal, A. (2002) · Arthritis Care & Research · doi:10.1002/art.10511 · Cited by 454
Shoji, A., Yamanaka, H., & Kamatani, N. (2004) · Arthritis Care & Research · doi:10.1002/art.20405 · Cited by 438
An Extremely Potent Inhibitor of Xanthine Oxidoreductase
Okamoto, K., Eger, B. T., Nishino, T., Kondo, S., Pai, E. F., & Nishino, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208307200 · Cited by 434
Allopurinol Hypersensitivity Syndrome: A Review
Arellano, F., & Sacristán, J. A. (1993) · Annals of Pharmacotherapy · doi:10.1177/106002809302700317 · Cited by 318
Wortmann, R. L. (2002) · Current Opinion in Rheumatology · doi:10.1097/00002281-200205000-00015 · Cited by 304
Self-citationPerez-Ruiz, F., Alonso-Ruiz, A., Calabozo, M., Herrero-Beites, A., García-Erauskin, G., & Ruiz-Lucea, E. (1998) · Annals of the Rheumatic Diseases · doi:10.1136/ard.57.9.545 · Cited by 257
The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality
Singer, J. Z., & Wallace, S. L. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780290111 · Cited by 245
Li‐Yu, J., Clayburne, G. M., Sieck, M. S., Beutler, A. M., Rull, M., Eisner, E. V., & Schumacher, H. R. (2001) · PubMed · Cited by 193
Self-citationHypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents
Osada, Y., Tsuchimoto, M., Fukushima, H., Takahashi, K., Kondo, S., Hasegawa, M., & Komoriya, K. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90201-r · Cited by 163
Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout
(2001) · CRC Press eBooks · doi:10.3109/9780203214237-143 · Cited by 158
Yamanaka, H., Togashi, R., Hakoda, M., Terai, C., Kashiwazaki, S., Dan, T., & Kamatani, N. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-5381-6_3 · Cited by 103
Becker, M. A., Kisicki, J. C., Khosravan, R., Wu, J., Mulford, D. J., Hunt, B., MacDonald, P., & Joseph‐Ridge, N. (2004) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1081/ncn-200027372 · Cited by 96
Self-citationHypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees
Komoriya, K., Osada, Y., Hasegawa, M., Horiuchi, H., Kondo, S., Couch, R. C., & Griffin, T. B. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90033-e · Cited by 70
Gout: can management be improved?
Schlesinger, N., & Schumacher, H. R. (2001) · Current Opinion in Rheumatology · doi:10.1097/00002281-200105000-00016 · Cited by 63
Self-citationHoriuchi, H., Ota, M., Kobayashi, M., Kaneko, H., Kasahara, Y., Nishimura, S., Kondo, S., & Komoriya, K. (1999) · PubMed · Cited by 49
Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient
Fam, A. G. (2001) · Current Rheumatology Reports · doi:10.1007/s11926-001-0048-8 · Cited by 48
Cited by
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Zhang, W., Doherty, M., Bardin, T., Pascual, E., Barskova, V, Conaghan, P., Gerster, J., Jacobs, J., Leeb, B., Lioté, F., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.055269 · Cited by 1,407
Schumacher, H. R., Becker, M. A., Wortmann, R. L., MacDonald, P. A., Hunt, B., Streit, J., Lademacher, C., & Joseph‐Ridge, N. (2008) · Arthritis Care & Research · doi:10.1002/art.24209 · Cited by 638
Self-citationJordan, K. M., Cameron, J. S., Snaith, M., Zhang, W., Doherty, M., Seckl, J., Hingorani, A., Jaques, R., & Nuki, G. (2007) · Rheumatology · doi:10.1093/rheumatology/kem056a · Cited by 552
Terkeltaub, R. A., Furst, D. E., Bennett, K., Kook, K. A., Crockett, R. S., & Davis, M. W. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27327 · Cited by 536
Metadata
- Authors
- Becker, M. A., Schumacher, H. R., Wortmann, R. L., MacDonald, P. A., Palo, W. A., Eustace, D., Vernillet, L., & Joseph‐Ridge, N.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-03
- Volume
- 52
- Issue
- 3
- Pages
- 916-923
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1988110621
- Cited by
- 266
- References
- 26
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.